Literature DB >> 17035443

Role of gastroesophageal reflux symptoms in exacerbations of COPD.

Ivan E Rascon-Aguilar1, Mark Pamer, Peter Wludyka, James Cury, David Coultas, Louis R Lambiase, N Stanley Nahman, Kenneth J Vega.   

Abstract

BACKGROUND AND AIMS: The impact of gastroesophageal reflux disease (GERD) on exacerbations of COPD has never been evaluated. The aims of this investigation were to determine the prevalence of gastroesophageal reflux (GER) symptoms in COPD patients and the effect of GER on the rate of exacerbations of COPD per year.
METHODS: A questionnaire-based, cross sectional survey was performed. Subjects were recruited from the outpatient pulmonary clinics at the University of Florida Health Science Center/Jacksonville. Included patients had an established diagnosis of COPD. Exclusion criteria were respiratory disorders other than COPD, known esophageal disease, active peptic ulcer disease, Zollinger-Ellison syndrome, mastocytosis, scleroderma, and current alcohol abuse. Those meeting criteria and agreeing to participate were asked to complete the Mayo Clinic GERD questionnaire by either personal/telephone interview. Clinically significant reflux was defined as heartburn and/or acid regurgitation weekly. Other outcome measures noted were frequency and type of COPD exacerbations. Statistical analysis was performed using the Fisher exact test for categorical data and the independent t test for interval data.
RESULTS: Eighty-six patients were enrolled and interviewed (mean age, 67.5 years). Male patients accounted for 55% of the study group. Overall, 37% of patients reported GER symptoms. The mean FEV(1) percentage of predicted was similar in those with or without GER. The rate of exacerbations of COPD was twice as high in patients with GER symptoms compared to those without GER symptoms (3.2/yr vs 1.6/yr, p = 0.02).
CONCLUSIONS: The presence of GER symptoms appears to be associated with increased exacerbations of COPD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17035443     DOI: 10.1378/chest.130.4.1096

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  54 in total

1.  Comparison of clinico-physiologic and CT imaging risk factors for COPD exacerbation.

Authors:  Jung-Wan Yoo; Yoonki Hong; Joon Beom Seo; Eun Jin Chae; Seung Won Ra; Ji-Hyun Lee; Eun Kyung Kim; Seunghee Baek; Tae-Hyung Kim; Woo Jin Kim; Jin Hwa Lee; Sang-Min Lee; Sangyeub Lee; Seong Yong Lim; Tae Rim Shin; Ho Il Yoon; Seung Soo Sheen; Jae Seung Lee; Jin Won Huh; Yeon-Mok Oh; Sang-Do Lee
Journal:  J Korean Med Sci       Date:  2011-11-29       Impact factor: 2.153

Review 2.  The Lung Microbiome and Its Role in Pneumonia.

Authors:  Benjamin G Wu; Leopoldo N Segal
Journal:  Clin Chest Med       Date:  2018-12       Impact factor: 2.878

3.  The lung tissue microbiome in chronic obstructive pulmonary disease.

Authors:  Marc A Sze; Pedro A Dimitriu; Shizu Hayashi; W Mark Elliott; John E McDonough; John V Gosselink; Joel Cooper; Don D Sin; William W Mohn; James C Hogg
Journal:  Am J Respir Crit Care Med       Date:  2012-03-15       Impact factor: 21.405

Review 4.  Long-term macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Ganapathi Iyer Parameswaran; Sanjay Sethi
Journal:  CMAJ       Date:  2014-08-05       Impact factor: 8.262

Review 5.  Lung microbiome for clinicians. New discoveries about bugs in healthy and diseased lungs.

Authors:  Leopoldo N Segal; William N Rom; Michael D Weiden
Journal:  Ann Am Thorac Soc       Date:  2014-01

6.  Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype.

Authors:  Leopoldo N Segal; Jose C Clemente; Jun-Chieh J Tsay; Sergei B Koralov; Brian C Keller; Benjamin G Wu; Yonghua Li; Nan Shen; Elodie Ghedin; Alison Morris; Phillip Diaz; Laurence Huang; William R Wikoff; Carles Ubeda; Alejandro Artacho; William N Rom; Daniel H Sterman; Ronald G Collman; Martin J Blaser; Michael D Weiden
Journal:  Nat Microbiol       Date:  2016-04-04       Impact factor: 17.745

7.  Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.

Authors:  Nicola J Sinden; Robert A Stockley
Journal:  Ther Adv Chronic Dis       Date:  2010-03       Impact factor: 5.091

8.  Pharmacotherapy and the risk for community-acquired pneumonia.

Authors:  Jen-Tzer Gau; Utkarsh Acharya; Salman Khan; Victor Heh; Lona Mody; Tzu-Cheg Kao
Journal:  BMC Geriatr       Date:  2010-07-06       Impact factor: 3.921

9.  Azithromycin and COPD Exacerbations in the Presence or Absence of Symptoms or Active Treatment for Gastroesophageal Reflux.

Authors:  Frederick L Ramos; Sarah M Lindberg; Jason S Krahnke; John Connett; Richard K Albert; Gerard J Criner
Journal:  Chronic Obstr Pulm Dis       Date:  2014-09-25

10.  Pulmonary manifestations of gastroesophageal reflux disease.

Authors:  Gajanan S Gaude
Journal:  Ann Thorac Med       Date:  2009-07       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.